by Katie Marquedant, Massachusetts General Hospital

Distribution of recurrent melanomas in the study population. Among the 310 recurrent melanomas, 255 (82%) recurred within five years and 285 (92%) recurred within 7 years of primary melanoma diagnosis. Credit: npj Precision Oncology (2022). DOI: 10.1038/s41698-022-00321-4

Most deaths from melanoma—the most lethal form of skin cancer—occur in patients who were initially diagnosed with early-stage melanoma and then later experienced a recurrence that is typically not detected until it has spread or metastasized.

A team led by investigators at Massachusetts General Hospital (MGH) recently developed an artificial intelligence-based method to predict which patients are most likely to experience a recurrence and are therefore expected to benefit from aggressive treatment. The method was validated in a study published in npj Precision Oncology.

Most patients with early-stage melanoma are treated with surgery to remove cancerous cells, but patients with more advanced cancer often receive immune checkpoint inhibitors, which effectively strengthen the immune response against tumor cells but also carry significant side effects.

"There is an urgent need to develop predictive tools to assist in the selection of high-risk patients for whom the benefits of immune checkpoint inhibitors would justify the high rate of morbid and potentially fatal immunologic adverse events observed with this therapeutic class," says senior author Yevgeniy R. Semenov, MD, an investigator in the Department of Dermatology at MGH.

"Reliable prediction of melanoma recurrence can enable more precise treatment selection for immunotherapy, reduce progression to metastatic disease and improve melanoma survival while minimizing exposure to treatment toxicities."

Non-recurrent melanomas were categorized into two groups: one group with a minimum of 5-year follow-up duration; another group 3:1 best matched to the recurrent melanomas in terms of follow-up duration. The first group was compared to recurrent melanomas in the binary recurrence classification tasks. The second group was compared to recurrent melanomas in the time-toevent recurrence prediction tasks. Credit: npj Precision Oncology (2022). DOI: 10.1038/s41698-022-00321-4

To help achieve this, Semenov and his colleagues assessed the effectiveness of algorithms based on machine learning, a branch of artificial intelligence, that used data from patient electronic health records to predict melanoma recurrence.

Specifically, the team collected 1,720 early-stage melanomas—1,172 from the Mass General Brigham healthcare system (MGB) and 548 from the Dana-Farber Cancer Institute (DFCI)—and extracted 36 clinical and pathologic features of these cancers from electronic health records to predict patients' recurrence risk with machine learning algorithms. Algorithms were developed and validated with various MGB and DFCI patient sets, and tumor thickness and rate of cancer cell division were identified as the most predictive features.

"Our comprehensive risk prediction platform using novel machine learning approaches to determine the risk of early-stage melanoma recurrence reached high levels of classification and time to event prediction accuracy," says Semenov. "Our results suggest that machine learning algorithms can extract predictive signals from clinicopathologic features for early-stage melanoma recurrence prediction, which will enable the identification of patients who may benefit from adjuvant immunotherapy."

Additional Mass General co-authors include Ahmad Rajeh, Michael R. Collier, Min Seok Choi, Munachimso Amadife, Kimberly Tang, Shijia Zhang, Jordan Phillips, Nora A. Alexander, Yining Hua, Wenxin Chen, Diane, Ho, Stacey Duey, and Genevieve M. Boland.

More information: Guihong Wan et al, Prediction of early-stage melanoma recurrence using clinical and histopathologic features, npj Precision Oncology (2022). DOI: 10.1038/s41698-022-00321-4

Journal information: npj Precision Oncology 

Provided by Massachusetts General Hospital